Birinapant is a developmental drug that is designed to restore the apoptosis functionality (programmed cell death) to cancer cells. The unusual dimeric molecule inhibits proteins that block apoptosis. TetraLogic Pharmaceuticals in Malvern, PA, is currently in early phase II clinical trials for using birinapant in leukemia, pancreatic cancer, and ovarian cancer patients.
Learn more about this molecule from CAS, the most authoritative and comprehensive source for chemical information.
Stay Ahead of the Chemistry Curve
Learn how ACS can help you stay ahead in the world of chemistry.